SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$34,105 | -$42,194 | -$18,741 | -$17,145 |
| Dep. & Amort. | $4,793 | $3,745 | $3,292 | $1,654 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $2,942 | $2,424 | $2,674 | $0 |
| Change in WC | -$2,299 | $2,326 | -$238 | $11,683 |
| Other Non-Cash | -$5,622 | $8,579 | -$10,447 | $5,795 |
| Operating Cash Flow | -$34,292 | -$25,119 | -$23,460 | $1,987 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$337 | -$197 | -$2,166 | -$10,944 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$37,446 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $25,821 | $0 | $0 | $0 |
| Other Inv. Act. | $0 | $44 | $76 | $0 |
| Investing Cash Flow | -$11,962 | -$153 | -$2,090 | -$10,944 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$907 | -$390 | -$1,185 | $1,544 |
| Stock Issued | $20 | $0 | $7,681 | $7 |
| Stock Repurch. | $0 | $0 | -$5,521 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$286 | $67,164 | $77 | $34,340 |
| Financing Cash Flow | -$1,173 | $66,773 | $1,051 | $35,891 |
| Forex Effect | -$241 | $18 | $0 | $0 |
| Net Chg. in Cash | -$47,668 | $41,519 | -$24,498 | $26,935 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $56,566 | $15,047 | $39,545 | $12,610 |
| End Cash | $8,898 | $56,566 | $15,047 | $39,545 |
| Free Cash Flow | -$34,629 | -$25,317 | -$25,626 | -$8,957 |